IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.187
AS - Asia 3.195
EU - Europa 1.431
SA - Sud America 621
Continente sconosciuto - Info sul continente non disponibili 277
AF - Africa 57
OC - Oceania 6
Totale 10.774
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.038
SG - Singapore 1.539
CN - Cina 773
IT - Italia 706
BR - Brasile 484
VN - Vietnam 307
IN - India 277
SE - Svezia 202
GB - Regno Unito 136
DE - Germania 116
CA - Canada 96
HK - Hong Kong 81
AR - Argentina 51
FI - Finlandia 48
BD - Bangladesh 35
MX - Messico 29
RO - Romania 28
EC - Ecuador 26
IQ - Iraq 25
NL - Olanda 24
ID - Indonesia 23
RU - Federazione Russa 23
CL - Cile 22
PL - Polonia 22
UA - Ucraina 22
JP - Giappone 21
ES - Italia 17
FR - Francia 16
EU - Europa 15
CZ - Repubblica Ceca 13
EG - Egitto 13
PK - Pakistan 13
PY - Paraguay 13
TR - Turchia 13
ZA - Sudafrica 13
VE - Venezuela 11
JO - Giordania 10
AE - Emirati Arabi Uniti 9
AT - Austria 9
IR - Iran 9
MY - Malesia 7
UZ - Uzbekistan 7
KE - Kenya 6
LT - Lituania 6
SA - Arabia Saudita 6
AU - Australia 5
CH - Svizzera 5
CO - Colombia 5
GR - Grecia 5
NP - Nepal 5
SC - Seychelles 5
YE - Yemen 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
EE - Estonia 4
HR - Croazia 4
IE - Irlanda 4
IL - Israele 4
MA - Marocco 4
MD - Moldavia 4
PH - Filippine 4
TN - Tunisia 4
UY - Uruguay 4
DZ - Algeria 3
HN - Honduras 3
KZ - Kazakistan 3
PA - Panama 3
PE - Perù 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
JM - Giamaica 2
KR - Corea 2
KW - Kuwait 2
LB - Libano 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CV - Capo Verde 1
CY - Cipro 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
Totale 10.507
Salva come PNG Salva come JPEG
Città #
San Jose 1.080
Singapore 511
Ashburn 464
Chandler 388
Santa Clara 290
Council Bluffs 244
Dallas 241
Hefei 225
Bengaluru 219
Milan 199
Princeton 192
Beijing 190
Lawrence 189
Catanzaro 139
Ho Chi Minh City 131
Wilmington 106
Chicago 97
London 90
Munich 84
Hong Kong 80
Phoenix 70
Hanoi 61
Los Angeles 61
Des Moines 57
Ottawa 47
São Paulo 47
Boardman 36
Turku 34
New York 32
Rio de Janeiro 26
Shanghai 25
Brooklyn 23
Haiphong 22
Rome 21
Redwood City 20
Warsaw 19
Boston 18
Montreal 18
Naples 18
Guangzhou 16
San Francisco 16
Helsinki 14
Horia 14
Pune 14
The Dalles 14
Da Nang 13
Norwalk 13
Tokyo 13
Olomouc 12
Stockholm 12
Baghdad 11
Bari 11
Manchester 11
Hanover 10
Mexico City 10
Redmond 10
Timisoara 10
Amman 9
Atlanta 9
Cosenza 9
Curitiba 9
Frankfurt am Main 9
Orem 9
Chennai 8
Columbus 8
Dhaka 8
Parma 8
Porto Alegre 8
Quito 8
Reggio Calabria 8
Santiago 8
Ann Arbor 7
Biên Hòa 7
Charlotte 7
Guayaquil 7
Jiaxing 7
Johannesburg 7
Lamezia Terme 7
Ovada 7
San Nicola Manfredi 7
Settingiano 7
Shenzhen 7
Tashkent 7
Toronto 7
Amsterdam 6
Belo Horizonte 6
Denver 6
Nairobi 6
Palermo 6
Salvador 6
Seattle 6
Thái Bình 6
Uberlândia 6
West Jordan 6
Andover 5
Ankara 5
Augusta 5
Aversa 5
Buffalo 5
Campinas 5
Totale 6.337
Salva come PNG Salva come JPEG
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 115
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 105
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 99
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 95
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 90
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 89
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer 85
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 83
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 83
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 81
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 81
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 79
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 79
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 78
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 76
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 76
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 76
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 75
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 73
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 73
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 73
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 73
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 71
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 71
In Vitro Silencing of lncRNAs Using LNA GapmeRs 71
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 70
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 69
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 69
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 69
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 69
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 69
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 69
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 68
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 67
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 67
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 66
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 66
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells 66
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 66
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 65
Contribution of PKB/AKT signaling to thyroid cancer 65
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 64
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 64
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 63
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 63
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 63
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 63
The non-coding RNA landscape of plasma cell dyscrasias 62
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 61
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 61
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 61
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 61
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 60
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 60
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 60
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 59
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 59
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 59
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 58
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 58
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 58
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 57
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 57
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 57
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity (CO-FIRST AUTHOR) 56
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 56
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 55
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 55
Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma 54
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 54
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 54
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 54
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 54
ZINC FINGER PROTEIN 521 (EHZF/ZNF521) ANTAGONIZES EARLY B-CELL FACTOR 1 AND MODULATES THE B-LYMPHOID DIFFERENTIATION OF PRIMARY HEMATOPOIETIC PROGENITORS 53
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. 53
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 53
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 53
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 52
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 52
Phoenixin-14: detection and novel physiological implications in cardiac modulation and cardioprotection 52
Protective role of GPER agonist g-1 on cardiotoxicity induced by doxorubicin 52
Biological Insights into Myeloma and Other B Cell Malignancies 52
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 52
Contribution of PKB/AKT signaling to thyroid cancer 51
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations 51
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 51
Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart 51
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 51
Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology 50
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 50
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 50
Palmitate-Induced Cardiac Lipotoxicity Is Relieved by the Redox-Active Motif of SELENOT through Improving Mitochondrial Function and Regulating Metabolic State 50
Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma 49
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 49
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 49
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 48
Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology 48
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 48
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 48
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 48
Totale 6.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.657
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.657
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022539 0 0 0 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024515 113 73 34 42 28 129 13 8 2 14 19 40
2024/20252.129 321 95 65 58 151 302 44 51 266 130 214 432
2025/20264.686 264 494 445 773 518 181 604 275 639 324 132 37
2026/20271.112 67 300 617 128 0 0 0 0 0 0 0 0
Totale 10.774